How to make the personalized antitumor vaccine and how it works (Image by NCNST)
Thanks to the rapid development of nanotechnology, a research team led by Profs. NIE Guangjun, WU Yan and ZHAO Yuliang from the National Center for Nanoscience and Technology (NCNST) of the Chinese Academy of Sciences (CAS) recently designed personalized tumor vaccines based on bacterial cytoplasmic membranes and cell membranes from resected tumor tissue. This work was published in Science Translational Medicine.
Cancer vaccines are an effective anti-tumor therapeutic option that utilize tumor antigens to stimulate patients’ immune response and specifically kill tumor cells. Postoperative recurrence and metastasis after surgery can thus be effectively inhibited by the activated immune system. Therefore, it is important for scientists and clinicians to find the best way to train the patient’s own immune system to find these tumor cells.
Using surgically removed tumor tissue is a very attractive way for making a patient’s own anti-cancer vaccine, since such a vaccine would contain the personalized antigen spectrum of the tumor cells. However, since there is only a small difference between the tumor antigens and the body’s own proteins, the antigens may be recognized as “self” by the patients’ own immune system. As a result, tumor antigens are more likely to induce antigen-specific tolerance than antitumor immunity.
Cancer immunotherapy faces the challenge of how to educate the immune system to distinguish tumor components as “non-self.” Most of the time, bacteria are easily identified as invaders and cleared out by the immune system. Some researchers have tried to use bacteria or their components as adjuvants to enhance immunogenicity. However, nonspecific stimulation of the immune system by bacteria or their components may elicit severe side effects.
For example, lipopolysaccharides—large molecules found in the cell walls of Gram negative bacteria—may cause lethal cytokine storms. Therefore, it is critically important to develop powerful anti-cancer vaccines that educate patients’ own immune systems to find cancer cells but do not induce side effects.
In this work, the research team designed a hybrid membrane nanovaccine for personalized immunotherapy to overcome the challenges described above. The tumor membrane antigens and bacterial inner membrane were fused and displayed on the surface of polymer nanoparticles. Introducing cytoplasmic membranes of E. coli, one of the most common bacteria in the human gut, into the hybrid membrane nanoparticle vaccines induced dendritic cell (DC) maturation, thus activating splenic T cells.
The hybrid membrane-coated nanoparticles represent a novel vaccine strategy that simultaneously delivers antigens and adjuvants to DCs to provoke robust innate and tumor-specific adaptive immune responses. In mouse tumor models, this strategy prevented tumor recurrence, with prolonged tumor-bearing animal survival and tumor-specific, long-term protection against tumor rechallenge.
In conclusion, this hybrid membrane-based antitumor immunity platform with intrinsic adjuvant properties offers a new opportunity for the development of individualized cancer vaccines for a broad range of solid tumors.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Personalized tumor vaccines
- New vaccine formulation protects newborn mice against respiratory syncytial virus (RSV)
Respiratory syncytial virus (RSV) is the leading global cause of death in children under age 5 and lacks an effective vaccine. In a study from the Precision Vaccines Program at Boston Children's ...
- Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
- Global Cancer/Tumor Profiling Market to Generate USD 31.67 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
Increase in new cancer cases with aging population & lifestyle changes and surge in adoption of precision medicine options drive the global cancer/tumor profiling market growth.New York, Aug. 01, 2022 ...
- Missed Out on Vaccine Stocks? My Best Biotech Stock to Buy and Hold
Coronavirus vaccine stocks soared for much of the past two years, but they've lost much of their momentum. Vaccine stocks probably won't deliver such rapid gains again. But over time, this vaccine ...
- Nutcracker Therapeutics Aims to Beat HPV-Driven Cancers With Multimodal mRNA Therapeutics
Nutcracker's lead compound, NTX-0250, is a multimodal mRNA therapeutic for HPV-driven tumors. Here, multimodal means that the product contains three different RNA molecules: a T cell-eliciting ...
Go deeper with Google Headlines on:
Personalized tumor vaccines
Go deeper with Bing News on:
- Realising the Promise of Cancer Vaccines
Realising the promise of cancer vaccinesFor years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason. The concept of pre-emptively ...
- New breast cancer treatment receives funding
Researchers at Queen’s University Belfast have received Breast Cancer Now funding to seek new treatments inspired by the COVID-19 vaccine.
- Giving HPV vaccine to older women could ward off cervical cancer
Study suggests giving jabs to women when they are being treated for precancerous lesions could halve risk of recurrence ...
- UW Health: Vaccine hesitancy in Wisconsin
VACCINATION FOR PEOPLE OF ALL AGES TO TALK MORE ABOUT VACCINE HESITANCY HERE IN WISCONSIN, DR. NOEL LE CONTE AND ONCOLOGIST WITH THE UW CANCER CENTER IS JOINING US NOELLE. THANK YOU FOR JOINING US ...
- EverCare Hospital Advocates Import of Cervical Cancer Vaccine
Cervical cancer is unique in having a preclinical stage when cancer has not developed which can last several years which if treated can stop the disease in its tracks. Which is why the early ...